Literature DB >> 3040184

Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat.

C Wahlestedt, G Skagerberg, R Ekman, M Heilig, F Sundler, R Håkanson.   

Abstract

Immunocytochemical studies have documented the presence of neuropeptide Y (NPY) in the hypothalamic paraventricular nucleus (PVN) which harbours a large number of neurones that contain corticotrophin-releasing factor (CRF). In this study the close morphological association between NPY fibres and CRF cell bodies in the PVN was confirmed. The localization of NPY terminals in the vicinity of CRF neurones forms a morphological basis for an action of NPY in the hypothalamic control of the pituitary-adrenocortical axis. We therefore microinjected NPY into the area of the PVN of both conscious, freely moving and anaesthetized rats and noted a powerful stimulatory effect on adrenocorticotropic hormone (ACTH) and corticosterone release as measured by radioimmunoassay. In experiments with conscious, freely moving rats, higher ACTH and corticosterone levels were detected following injection of NPY into the area of the PVN than following control injection (desamidated NPY). Intracerebroventricular injection of NPY produced a small, albeit significant, increase in circulating corticosterone levels as compared to control (saline-injected) rats. Anaesthetized rats responded to NPY (but not to saline) injected into the area of the PVN with elevated ACTH and corticosterone levels, while injection of NPY into the neocortex failed to affect the blood concentration of either ACTH or corticosterone. In conclusion, we have demonstrated an activating effect of NPY on the pituitary-adrenocortical axis both in conscious and anaesthetized rats which may reflect the anatomical relationship between NPY fibres and CRF neurones in the PVN.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040184     DOI: 10.1016/0006-8993(87)90176-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

1.  Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release.

Authors:  C J Small; D G Morgan; K Meeran; M M Heath; I Gunn; C M Edwards; J Gardiner; G M Taylor; J D Hurley; M Rossi; A P Goldstone; D O'Shea; D M Smith; M A Ghatei; S R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 2.  Hungry for life: How the arcuate nucleus and neuropeptide Y may play a critical role in mediating the benefits of calorie restriction.

Authors:  Robin K Minor; Joy W Chang; Rafael de Cabo
Journal:  Mol Cell Endocrinol       Date:  2008-11-11       Impact factor: 4.102

3.  Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models.

Authors:  M Heilig; B Söderpalm; J A Engel; E Widerlöv
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Neuroendocrine effects of leptin.

Authors:  F P Pralong; R C Gaillard
Journal:  Pituitary       Date:  2001 Jan-Apr       Impact factor: 4.107

Review 5.  Interacting Neural Processes of Feeding, Hyperactivity, Stress, Reward, and the Utility of the Activity-Based Anorexia Model of Anorexia Nervosa.

Authors:  Rachel A Ross; Yael Mandelblat-Cerf; Anne M J Verstegen
Journal:  Harv Rev Psychiatry       Date:  2016 Nov/Dec       Impact factor: 3.732

6.  Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophysial-portal circulation of the conscious sheep. II. The central noradrenergic and neuropeptide Y pathways cause immediate and prolonged hypothalamic-pituitary-adrenal activation. Potential involvement in the pseudo-Cushing's syndrome of endogenous depression and anorexia nervosa.

Authors:  J P Liu; I J Clarke; J W Funder; D Engler
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

7.  Orexin a stimulates hypothalamic-pituitary-adrenal (HPA) axis function, but not food intake, in the absence of full hypothalamic NPY-ergic activity.

Authors:  Griselda Moreno; Mario Perelló; Rolf C Gaillard; Eduardo Spinedi
Journal:  Endocrine       Date:  2005-03       Impact factor: 3.633

8.  Effects of centrally administered neuropeptide Y (NPY) and NPY13-36 on the brain monoaminergic systems of the rat.

Authors:  M Heilig; L Vècséi; C Wahlestedt; C Alling; E Widerlöv
Journal:  J Neural Transm Gen Sect       Date:  1990

9.  Localization of neuropeptide Y-immunoreactive cells and fibres in the brain of the Japanese quail.

Authors:  N Aste; C Viglietti-Panzica; A Fasolo; C Andreone; H Vaudry; G Pelletier; G C Panzica
Journal:  Cell Tissue Res       Date:  1991-08       Impact factor: 5.249

10.  Synaptic regulation of paraventricular arginine vasopressin-containing neurons by neuropeptide Y-containing monoaminergic neurons in rats. Electron-microscopic triple labeling.

Authors:  Y Kagotani; Y Tsuruo; S Hisano; S Daikoku; K Chihara
Journal:  Cell Tissue Res       Date:  1989-08       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.